Catalio Capital closes over $400M Fund IV

Catalio Capital Management has successfully closed its latest investment vehicle, Fund IV, amassing over $400 million to further its commitment to the healthcare and biotechnology sectors. This milestone was initially highlighted by Bloomberg. Founded in 2020, Catalio has made significant strides in the venture capital landscape, executing over 100 investments to date, as reported by PitchBook. Fund IV has already made its mark by investing in 16 companies, including PinkDx, a diagnostics innovator, and Superluminal Medicines, which focuses on drug discovery. This latest fund follows Catalio's previous fundraising efforts, which included a $381 million Fund III launched in 2020 and a $100 million Fund II in 2019. Despite the challenges faced by the biotech market amid a venture capital downturn, marked by rising interest rates and a subdued IPO environment, Catalio remains steadfast in its investment strategy. The overall biotech sector raised only $12 billion last year, a significant drop from the record $152.3 billion raised in 2023, according to Bloomberg.